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increase	 in	KRAS	mutations	 (35.3%)	and	PD-	L1	 (<1%)	expression	 (55.6%).	Re-	
expression	of	tumoral	ASS1	was	detected	in	one	patient	at	progression	(n = 1/3).
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1 	 | 	 INTRODUCTION
Globally,	lung	cancer	is	the	leading	cause	of	cancer-	related	
mortality,	 accounting	 for	 almost	 one	 in	 five	 deaths.1	
Around	85%	of	 lung	cancer	patients	have	non-	small	cell	




NSCLC–	–	in	 the	 absence	 of	 an	 oncogenic	 driver	 such	 as	
an	 EGFR	 mutation	 or	 ALK	 translocation–	–	is	 immune	
checkpoint	blockade	either	alone	or	in	combination	with	
platinum-	based	chemotherapy	(pemetrexed	or	paclitaxel-	


















deprivation	 with	 pegylated	 arginine	 deiminase	 (ADI-	





recognized	 as	 a	 prognostic	 biomarker	 for	 poor	 survival	
outcomes	 in	 several	 cancer	 types,	 including	 mesotheli-
oma,	 sarcomas,	 bladder,	 ovarian,	 and	 breast	 cancer	 by	
driving	 increased	 tumor	 cell	 proliferation,	 invasiveness,	
and	 metastasis.8–	14	 Moreover,	 based	 on	 data	 from	 The	
Cancer	Genome	Atlas	(TCGA),	ASS1 loss	confers	signifi-
cantly	 reduced	 5-	year	 survival	 rates	 (25%	 “low”	 vs.	 44%	
“high”	ASS1	expression;	p = 0.007;	n = 500)	for	all	stages	
of	 lung	 adenocarcinoma,	 including	 patients	 in	 adjuvant	















thoracic	 cancers	 (non-	squamous	 NSCLC  =  4;	 mesothe-




estimates.	 Recently,	 we	 have	 reported	 on	 the	 safety	 and	
activity	 of	 ADIPemCis	 in	 dose-	expansion	 cohorts	 in	 pa-
tients	with	high-	grade	glioma	(n = 10),	malignant	pleural	
mesothelioma	(n = 31),	and	a	placebo-	controlled	phase	3	
trial	 of	 ADIPemCis	 is	 now	 underway	 in	 non-	epithelioid	
mesothelioma	based	on	a	robust	survival	signal.17,18
Therefore,	 we	 tested	 the	 hypothesis	 that	 targeting	
essential	 arginine	 would	 benefit	 patients	 with	 non-	
squamous	 NSCLC	 characterized	 by	 loss	 of	 the	 ASS1	
tumor	 suppressor.	 We	 treated	 a	 dose-	expansion	 cohort	
of	 21	 patients	 with	 ASS1-	deficient	 non-	squamous	 non-	
small	cell	lung	cancer	at	the	recommended	phase	2	dose	
(RP2D)	of	ADI-	PEG	20	(36 mg/m2)	in	combination	with	
standard	 doses	 of	 pemetrexed	 and	 cisplatin.	 The	 main	
aims	 of	 this	 phase	 1	 dose-	expansion	 study	 were	 to	 de-
fine	 further	 the	 safety,	 preliminary	 activity,	 and	 survival	
estimates	of	the	ADIPemCis	triplet	in	patients	with	non-	









Conclusions: ADIPemCis	 was	 safe	 and	 highly	 active	 in	 patients	 with	 ASS1-	
deficient	non-	squamous	NSCLC,	however,	survival	was	poor	overall.	ASS1 loss	
was	 co-	associated	 with	 p53  mutations.	 Therapies	 incorporating	 pegargiminase	
merit	further	evaluation	in	ASS1-	deficient	and	treatment-	refractory	NSCLC.
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2 	 | 	 PATIENTS AND METHODS
2.1	 |	 Patient eligibility
Patients	 were	 aged	 18  years	 or	 over,	 with	 histologically	
proven	 argininosuccinate	 synthetase	 1	 (ASS1)-	deficient	
stage	IIIB	or	IV	non-	squamous	NSCLC	(v.	Beddowes	et	al.	
for	methods).	Patients	had	evaluable	disease	by	Response	
Evaluation	 Criteria	 in	 Solid	 Tumors	 criteria	 (RECIST)	
1.1.	All	patients	were	chemotherapy	naïve.	Subjects	with	
EGFR	or	ALK	mutation	must	have	had	an	EGFR	tyros-
ine	 kinase	 inhibitor	 (TKI)	 or	 ALK	 inhibitor,	 and	 must	
have	 progressed	 or	 been	 shown	 to	 be	 intolerant	 of	 this	




tancy.	 Exclusion	 criteria	 included	 symptomatic	 brain	 or	


















first	 dose.	 Patients	 received	 a	 maximum	 of	 four	 cycles	





of	 disease	 or	 study	 withdrawal.	 Baseline	 tumor	 biopsies	
were	mandatory	and	were	optional	at	disease	progression.
2.3	 |	 Study endpoints
The	data	lock	was	performed	on	the	18 June	2020.	The	
primary	 endpoints	 of	 the	 dose-	expansion	 phase	 were	
to	 assess	 the	 safety	 and	 tolerability	 of	 ADIPemCis	
using	National	Cancer	Institute	Common	Terminology	
Criteria	 for	 Adverse	 Events	 (CTCAE)	 Version	 4.03;	
and	 to	 estimate	 the	 preliminary	 efficacy	 or	 response	
rate	 (RR)	 using	 RECIST	 1.1,	 by	 computed	 tomogra-
phy	 (CT)	 every	 6  weeks	 during	 ADIPemCis	 therapy	
and	then	every	8 weeks	during	pegargiminase	or	pem-
etrexed	 maintenance	 therapy.	 Secondary	 endpoints	
were	 to	calculate	 the	median	progression-	free	survival	
(PFS),	median	overall	 survival	 (OS),	pharmacodynam-
ics,	 and	 immunogenicity.	 For	 the	 translational	 end-
points,	 next-	generation	 sequencing	 was	 performed	 on	
baseline	 tumor	 DNA	 examining	 the	 different	 somatic	
variants	 detected	 using	 Ion	 AmpliSeq	 Cancer	 Hotspot	
Panel	v2	(Thermo	Fisher	Scientific).	PD-	L1	expression	
was	 assessed	 using	 the	 22C3	 immunohistochemistry	
(IHC)	 assay	 and	 reported	 according	 to	 the	 standard	
criteria	 (>50%;	 1%–	49%;	 <1%	 expression).	 Rebiopsied	
tumor	 tissue	 at	 relapse	 was	 assessed	 for	 ASS1	 IHC	
using	 the	 monoclonal	 antibody	 195-	21-	1	 from	 Polaris	
Pharmaceuticals,	Inc.
2.4	 |	 Statistical analyses
No	formal	sample	size	calculation	was	made	for	the	dose-	





3 	 | 	 RESULTS




21	 patients	 with	 ASS1-	deficient	 tumors	 were	 enrolled	
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were	included	for	the	safety,	while	19	were	evaluable	by	
RECIST	1.1	(Table 1).	Patients	with	ASS1-	proficient	non-	




Consistent	 with	 the	 prior	 dose-	escalation	 study,	
ADIPemCis	 treatment	 was	 well-	tolerated.	 Treatment-	








tients,	 the	 latter	 due	 to	 disease	 progression	 (Table  2;	
Table S1).
3.3	 |	 Pharmacodynamics
Pegargiminase	 decreased	 plasma	 arginine	 with	 a	 re-
ciprocal	 increase	 in	 plasma	 citrulline	 levels	 in	 patients	
and	 is	 shown	 in	 Figure  2A.	 Plasma	 levels	 of	 the	 amino	
acids	remained	differentially	altered	compared	with	pre-	
treatment	levels,	however,	recovery	to	pre-	treatment	lev-
els	 was	 evident	 with	 the	 fewer	 number	 of	 on-	treatment	




ADIPemCis	 treatment	 induced	 a	 disease	 control	 rate	 of	
85.7%	 (n  =  18/21;	 95%	 CI	 63.7%–	97%),	 and	 a	 partial	 re-
sponse	 rate	 of	 47.6%	 (n  =  10/21,	 95%	 CI	 25.7%–	70.2%;	
or	n = 10/18	or	55.6%	of	evaluable	patients),	in	a	cohort	
of	 patients	 with	 non-	squamous	 NSCLC	 enriched	 by	
ASS1 loss,	summarized	in	Figure 2C,D.	The	median	PFS	
F I G U R E  1  CONSORT	diagram
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and	OS	were	4.2	(95%	CI	2.9–	4.8)	and	7.2	(95%	CI	5.1–	18.4)	
months,	respectively,	and	are	shown	in	Figure 3.





and	 KRAS	 mutations	 in	 35.3%	 of	 patients	 (G12C,	 G13C,	
G12D,	and	Q61H)	in	ASS1-	deficient	non-	squamous	NSCLC.	





tumoral	 PD-	L1	 ≥1%	 expression	 and	 disease	 progression	
were	eligible	 for	 second-	line	pembrolizumab;	 two	patients	
are	in	remission	at	40	and	47 months	from	treatment	with	
ADIPemCis	 following	 2  years	 of	 immunotherapy	 (9.5%).	
Finally,	 to	 study	 drug	 resistance,	 three	 patients	 receiving	
maintenance	ADI-	PEG20	consented	to	a	rebiopsy	revealing	
ASS1	re-	expression	in	one	patient	(n = 1/3;	33%).
3.6	 |	 ASS1- positive group
Retrospectively,	we	determined	the	median	OS	of	patients	
with	 ASS1-	proficient	 non-	squamous	 NSCLC	 screened	
as	part	of	this	study	(n = 35).	Following	exclusion	of	six	
ASS1-	positive	patients	with	EGFR	mutations,	who	all	re-
ceived	 first-	line	 therapy	with	a	 tyrosine	kinase	 inhibitor	
(TKI:	gefitinib,	erlotinib,	or	afatinib),	 the	median	OS	for	
patients	 receiving	 first-	line	platinum	(cisplatin	or	carbo-
platin)	 and	 pemetrexed	 chemotherapy	 was	 10.2  months	
(n = 29;	95%	CI	5.9–	17.3)	and	is	depicted	in	Figure 4.	This	




4 	 | 	 DISCUSSION
This	 expansion	 study	 of	 ADIPemCis	 at	 the	 RP2D	 con-
firmed	good	safety	and	a	high	rate	of	disease	control	and	





compared	 with	 ASS1-	agnostic	 historical	 controls	 (10.4–	
12.6  months)	 treated	 with	 platinum	 and	 pemetrexed	
T A B L E  1 	 Demographics	of	patients	receiving	ADIPemCis
Characteristic
























T A B L E  2 	 Overall	adverse	events
Overall AEa summary
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alone.20	 Notably,	 p53	 and	 KRAS	 mutations	 were	 co-	
associated	 with	 ASS1-	deficient	 non-	squamous	 NSCLC	
contributing	to	the	poor	clinical	outcomes;	PD-	L1	expres-
sion	 was	 commonly	 absent	 (<1%	 staining	 by	 the	 22C3	
assay).	 In	 contrast,	 EGFR-	mutant	 and	 ALK	 rearranged	
non-	squamous	NSCLC	 tumors	were	all	ASS1-	expressors	
for	 which	 TKI	 therapies	 have	 revolutionized	 patient	
management.
Since	 completing	 the	 ADIPemCis	 dose-	expansion	
cohort,	 chemoimmunotherapy	 with	 PD1	 and	 PD-	L1	 in-




for	 atezolizumab	 with	 bevacizumab,	 carboplatin,	 and	
paclitaxel	 (vs.	 14.7  months	 for	 bevacizumab,	 carbopla-
tin,	and	paclitaxel)	in	the	IMpower150 study.21,22	Further	
optimization	of	chemoimmunotherapy	especially	 in	PD-	







or	 CDKN2A	 which	 are	 known	 to	 upregulate	 cancer	 im-
mune	responses	in	NSCLC.25,26
PD-	L1	 <1%	 expression	 was	 reported	 in	 55.6%	 of	 pa-
tients	 enrolled	 on	 ADIPemCis,	 a	 prevalence	 that	 is	 sig-
nificantly	higher	than	that	reported	across	key	studies	of	
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pembrolizumab	in	NSCLC	(33%),	but	consistent	with	real-	
world	 data	 (48%–	56.4%).27–	29	 Recent	 work	 suggests	 that	
arginine	deprivation	may	potentiate	immune	checkpoint	
inhibition	and	turn	“cold”	tumors	“hot”	by	increasing	the	
PD-	L1	 expression	 and	 T-	cell	 infiltration.30,31	 Moreover,	
urea	 cycle	 dysregulated	 cancers	 are	 differentially	 sen-
sitive	 to	 immune	 checkpoint	 therapies	 and	 further	 clin-
ical	 testing	 will	 be	 needed	 to	 validate	 these	 preclinical	
data.32	Specifically,	a	phase	1 study	of	pembrolizumab	and	
pegargiminase	has	completed	accrual	and,	while	patients	
with	 NSCLC	 were	 not	 enrolled,	 this	 immunometabolic	
approach	 was	 tolerable	 with	 partial	 responses	 in	 24%	 of	
subjects.33
The	 41%	 higher	 prevalence	 of	 p53  mutations	 in	 our	
study	compared	to	that	expected	for	patients	with	LUAC	




T A B L E  3 	 Individual	patient	and	tumor	characteristics
Subject Age Gender Diagnosis Disease presentation
PD- L1 
expressiona 
NGS somatic variantsb 
TP53 KRAS Other
101-	301 64 M ADC Lung,	LN <1% WT G12C
101-	302 54 M ADC LN,	Adrenal >50% R158L WT
101-	303 51 F ADC Lung N/A N/A N/A
101-	304 60 M ADC Lung 3% G245V G12C
101-	305 45 M Large	cell Lung,	LN,	Peritoneal <1% G334V WT
101-	306 58 M ADC Lung,	LN N/A WT WT
101-	307 56 F ADC Lung,	LN,	Bone <1% WT G12D
101-	308 68 M ADC LN,	Bone,	Muscle <1% R248Q WT ATM
101-	309 63 M ADC Lung,	LN <1% N/A N/A
101-	310 63 F ADC LN,	Bone 5%–	10% G199V WT BRAF	(V600E)
101-	311 39 M ADC Lung,	LN,	Liver <1% N/A N/A
101-	312 62 M ADC Lung,	Adrenal,	Bone <1% WT Q61H
101-	313 60 F ADC Lung,	LN,	Pleural,	
Pericardial	Bone
80%–	90% E285V G13C
101-	314 50 M ADC Lung,	LN,	Liver,	
Pleural
<1% WT WT
101-	315 65 M Giant	cell Lung,	LN,	Adrenal 100% Y126D WT
101-	316 60 F ADC Lung,	LN,	Adrenal <1% WT G12D APC
101-	317 59 F ADC Lung,	LN,	Liver,	Bone <1% G244R WT RB1; ERBB2
101-	318 53 M ADC Lung 10%–	20% G245V WT CDKN2A; 
HRAS
101-	319 70 M ADC Lung,	LN 60%–	70% R248L WT
101-	320 78 M ADC Lung,	LN 60%–	70% R249T WT JAK3	P132T
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tumor	 suppressor	 pathway.35,36	 Specifically,	 transfection	
of	wild-	type	p53	in	p53-	deficient	(NSCLC)	or	p53-	mutant	




links	 various	 p53  mutations	 to	 deregulation	 of	 ASS1	 in	
clinical	 samples	 for	 the	 first	 time,	 and	 also	 provides	 an	
explanation	for	the	poor	overall	survival	seen	in	the	non-	







a	 taxane	 potentiates	 gemcitabine	 cytotoxicity,	 and	 is	 an	
approach	that	may	have	utility	in	patients	with	squamous	
NSCLC.41	 Interestingly,	 our	 NSCLC	 cohort	 data	 validate	
studies	showing	high	rates	of	ASS1 loss	in	non-	epithelioid	
mesothelioma,	 where	 p53  mutations	 have	 been	 identi-
fied	 to	 the	 exclusion	 of	 epithelioid	 mesothelioma,	 and	
underlie	similar	poor	outcomes	to	platinum–	pemetrexed	
chemotherapy.42,43
Mutations	 in	 KRAS	 were	 the	 second	 most	 common	
finding	 by	 NGS	 in	 our	 patient	 cohort	 with	 a	 modestly	
higher	 prevalence	 compared	 to	 patients	 with	 unselected	
LUAC	 reported	 in	 the	 recent	 published	 AACR	 Project	
GENIE,	 namely	 35.3%	 versus	 26.7%.44	 However,	 KRAS	
mutations	have	been	described	with	a	 frequency	of	33%	
in	the	TCGA	dataset	for	LUAC	thus	a	molecular	link	with	
ASS1	 requires	 additional	 scrutiny.45	Two	 patients	 in	 our	
study	achieved	PRs	on	ADIPemCis	despite	co-	mutations	
of	p53	and	KRAS	mutations	which	portend	a	poor	survival	








inase	 inhibition	 in	 KRAS-	mutant	 LUAC.49	 Site-	specific	
differences	have	also	been	reported	in	the	median	OS	for	
patients	 with	 KRAS	 mutations	 and	 LUAC:	 3.7  months	
for	bone	metastases	versus	9.7 months	without	bone	 in-
volvement.50	 Importantly,	 the	 recent	 development	 of	
K12C-	targeted	drugs	will	leverage	novel	opportunities	for	




As	 noted	 earlier,	 several	 studies	 reinforce	 that	 ASS1	
deficiency	is	a	poor	prognostic	biomarker	 in	a	variety	of	
solid	malignancies.8–	14,16	In	the	present	study,	the	median	
OS	 for	 ASS1-	deficient	 compared	 to	 ASS1-	proficent	 pa-






namely,	 tumoral	 re-	expression	 of	 ASS1,	 stromal	 support	
via	infiltrating	macrophages	identified	in	the	earlier	me-
sothelioma	TRAP	dose-	expansion	cohort,	and	potentially	
drug-	dependent	 resistance,	 evidenced	 by	 an	 increasing	
titer	of	pegargiminase	antibodies	and	a	concomitant	rise	
in	 arginine	 levels	 by	 week	 16.17	While	 the	 pharmacody-













may	 provide	 additional	 therapeutic	 benefit	 warranting	
further	investigation	with	rationally	selected	agents.
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